Alpha 2.0
Login Register
» Authors » Lipontso Makakole

Lipontso Makakole

Explore the profile of Lipontso Makakole including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 189
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Helen Bygrave
Nathan Ford
Katherine Hilderbrand
Eric Goemaere
Guillaume Jouquet
Katharina Kranzer
Laura Trivino
Nathalie Vlahakis
Natalie Vlahakis
Peter Saranchuk
Published In
J Acquir Immune Defic Syndr
PLoS One
J Int AIDS Soc
Int Health
AIDS
Affiliations
Soon will be listed here.
Recent Articles
1.
Feasibility and benefits of scaling up antiretroviral treatment provision with the 2010 WHO antiretroviral therapy guidelines in rural Lesotho
Bygrave H, Saranchuk P, Makakole L, Ford N
Int Health . 2013 Sep; 4(3):170-5. PMID: 24029396
The latest WHO guidelines (2010) for antiretroviral therapy (ART) in adults and adolescents recommend that countries should progressively reduce the use of stavudine in favour of tenofovir or zidovudine and...
2.
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho
Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, et al.
J Acquir Immune Defic Syndr . 2011 Jul; 58(3):e68-74. PMID: 21765366
Background: Latest World Health Organization guidelines recommend shifting away from Stavudine (d4T)-based regimens due to severe side effects. However, widespread replacement of d4T by Tenofovir (TDF) or Zidovudine (AZT) is...
3.
Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho
Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al.
PLoS One . 2011 Mar; 6(3):e17609. PMID: 21407815
Introduction: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function...
4.
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years
Bygrave H, Ford N, Van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, et al.
J Acquir Immune Defic Syndr . 2010 Dec; 56(3):e75-8. PMID: 21164354
Background: The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on...
5.
Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho
Ford N, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al.
AIDS . 2010 Oct; 24(17):2645-50. PMID: 20980868
Introduction: The latest WHO guidelines recommend initiating antiretroviral therapy (ART) at CD4 cell counts less than 350 cells/μl. However, donors and national governments are reluctant to support implementation owing to...
6.
Trends in loss to follow-up among migrant workers on antiretroviral therapy in a community cohort in Lesotho
Bygrave H, Kranzer K, Hilderbrand K, Whittall J, Jouquet G, Goemaere E, et al.
PLoS One . 2010 Oct; 5(10):e13198. PMID: 20976289
Background: The provision of antiretroviral therapy (ART) to migrant populations raises particular challenges with respect to ensuring adequate treatment support, adherence, and retention in care. We assessed rates of loss...
7.
Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years
Cohen R, Lynch S, Bygrave H, Eggers E, Vlahakis N, Hilderbrand K, et al.
J Int AIDS Soc . 2009 Oct; 12:23. PMID: 19814814
Introduction: Lesotho has the third highest HIV prevalence in the world (an adult prevalence of 23.2%). Despite a lack of resources for health, the country has implemented state-of-the-art antiretroviral treatment...